Clinical Trials Sponsored by University of Michigan Rogel Cancer Center

Total 14124 results

University of Michigan Rogel Cancer Center

Recruiting

Trial of Individualized Adaptive RT in HPV-related High Risk Oropharynx Cancer (ARTHOUSE)

Oropharynx Cancer | HPV-Related Carcinoma

United States
University of Michigan Rogel Cancer Center

Not yet recruiting

Breast Cancer Resiliency Through Exercise Program (B-REP) (B-REP)

Breast Cancer Female

United States
University of Michigan Rogel Cancer Center

Not yet recruiting

Effect of Pre-operative Virtual Visits on Patients With Head and Neck Cancer Undergoing Surgery

Head and Neck Cancer
University of Michigan Rogel Cancer Center

Not yet recruiting

Feasibility of Virtual, Tailored, Music-Based Relaxation for Anxiety in Adolescent and Young Adult Cancer Survivors

Anxiety

United States
University of Michigan Rogel Cancer Center

Recruiting

A Pilot Study of Liver Protection Using Prednisone for Patients Receiving Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma

Hepatocellular Carcinoma

United States
University of Michigan Rogel Cancer Center

Recruiting

Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Breast Cancer

Breast Cancer

United States
University of Michigan Rogel Cancer Center

Recruiting

Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I)

Metastatic Melanoma | Liver Metastases | Melanoma, Mucosal | Melanoma, Ocular | Melanoma, Cutaneous

United States
University of Michigan Rogel Cancer Center

Recruiting

Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])

Prostate Cancer

United States
University of Michigan Rogel Cancer Center

Recruiting

Imaging Properties of PET Radiotracer [18F]3F-PHPG in Patients With Neuroendocrine Tumors

Neuroendocrine Tumors

United States
University of Michigan Rogel Cancer Center

Recruiting

Acupressure for Fatigue in Ovarian Cancer Survivors

Fatigue | Ovarian Cancer

United States
University of Michigan Rogel Cancer Center

Recruiting

Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer

Metastatic Thyroid Cancer

United States
University of Michigan Rogel Cancer Center

Recruiting

Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients

Hematopoietic Stem Cell Transplantation

United States
University of Michigan Rogel Cancer Center

Terminated

Multi-center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic Renal Cell Carcinoma (ERICA)

Renal Cell Carcinoma, Metastatic

United States
University of Michigan Rogel Cancer Center

Completed

FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)

Prostate Cancer

United States
University of Michigan Rogel Cancer Center

Completed

A Pilot Study of Roadmap 2.0 in Oncology Caregivers and Patients

Quality of Life | Cancer

United States
University of Michigan Rogel Cancer Center

Suspended

Study Using Genomic, Histologic and Radiomic Analysis to Evaluate Regional Tumor Heterogeneity in Patients Undergoing Surgery for Newly Diagnosed Glioblastoma

Glioblastoma

United States
University of Michigan Rogel Cancer Center

Terminated

Pilot Study of Bone Biopsy and Aspirate in Women With Metastatic Breast Cancer

Metastatic Breast Cancer

United States
University of Michigan Rogel Cancer Center

Completed

A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States
University of Michigan Rogel Cancer Center

Completed

Chemotherapy AND Bcl-xL Inhibitor (AT-101) For Organ Preservation In Adults With Advanced Laryngeal Cancer

Laryngeal Cancer

United States
University of Michigan Rogel Cancer Center

Completed

Phase II Treatment Stratification Trial Using Neck Dissection-Driven Selection to Improve Quality of Life for Low Risk Patients With HPV+ Oropharyngeal Squamous Cell Cancer

Oropharyngeal Squamous Cell Cancer

United States
University of Michigan Rogel Cancer Center

Terminated

Radiolabeled Gallium-68 (68Ga-PSMA) for PET/CT Imaging to Detect Prostate Cancer

Prostate Cancer

United States
University of Michigan Rogel Cancer Center

Completed

Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies

Hematologic Malignancies | Graft-Versus-Host Disease | Relapse

United States
University of Michigan Rogel Cancer Center

Completed

Phase Ib/II Trial of Interleukin-2 and PD-1 Checkpoint Inhibitor, Nivolumab In Metastatic Clear Cell Renal Cell Cancer

Renal Cell Carcinoma

United States
University of Michigan Rogel Cancer Center

Terminated

Study of Radiation (RT) Concurrent With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (SCC)

Head and Neck Cancer

United States
University of Michigan Rogel Cancer Center

Completed

Reduced-intensity Therapy for Oropharyngeal Cancer in Non-smoking HPV-16 Positive Patients

HPV | Squamous Cell Carcinoma of the Oropharynx

United States
University of Michigan Rogel Cancer Center

Withdrawn

Abemaciclib With or Without Atezolizumab in Metastatic Castration Resistant Prostate Cancer

Prostate Cancer

United States
University of Michigan Rogel Cancer Center

Withdrawn

Bortezomib in Combination With Ibrutinib in Ibrutinib Relapsed Mantle Cell Lymphoma

Mantle Cell Lymphoma

United States
University of Michigan Rogel Cancer Center

Completed

Assessment Of Liver Function in Patients Undergoing Hepatic Irradiation (IC-Green)

Hepatic Irradiation

United States
University of Michigan Rogel Cancer Center

Completed

Using Imaging and Molecular Markers to Predict Tumor Response and Lung Toxicity in Lung Cancer

Non-Small Cell Lung Cancer

United States
University of Michigan Rogel Cancer Center

Completed

The Validation of a Novel Adherence Method for Oral Oncolytics

Cancer

United States
University of Michigan Rogel Cancer Center

Withdrawn

A Study of Panobinostat in Combination With Everolimus for Children and Young Adults With Gliomas

Glioma | Diffuse Intrinsic Pontine Glioma

United States
University of Michigan Rogel Cancer Center

Terminated

Radium-223 and Atezolizumab in Patients With Urothelial Carcinoma With Bone Metastases Who Have Had Disease Progression After Platinum-Based Chemotherapy

Urothelial Carcinoma

United States
University of Michigan Rogel Cancer Center

Completed

Vorinostat Plus Tacrolimus & Methotrexate to Prevent Graft vs Host Disease Following Unrelated Stem Cell Transplant

Hematologic Neoplasms | Graft vs Host Disease | Non-Neoplastic Hematologic and Lymphocytic Disorder

United States
University of Michigan Rogel Cancer Center

Completed

Patient and Caregiver Participation Through an Educational Health Information Technology System ("BMT Roadmap") in the Context of Hematopoietic Cell Transplantation

Patients Undergoing Bone Marrow Transplant (BMT)

United States
University of Michigan Rogel Cancer Center

Completed

Open-label, Phase II Study of MLN9708 in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell Lymphomas

Lymphoma, T-Cell

United States
University of Michigan Rogel Cancer Center

Completed

A Pilot Study of Tumor Cell Vaccine for High-risk Solid Tumor Patients Following Stem Cell Transplantation

Sarcoma | Neuroblastoma | Wilm's Tumor

United States
University of Michigan Rogel Cancer Center

Terminated

Prospective Study Evaluating the Use of PROSPECT to Reduce Insomnia in Patients With Early Stage Breast Cancer

Breast Cancer | Insomnia

United States
University of Michigan Rogel Cancer Center

Completed

A Pilot Study of Diffusion MRI in the Assessment of Pancreatic Tumor Response

Pancreatic Cancer

United States
University of Michigan Rogel Cancer Center

Completed

Defining an Exposure Target for Weekly Paclitaxel Infusion in Breast Cancer Patients

Breast Cancer

United States
University of Michigan Rogel Cancer Center

Withdrawn

Study of Tocilizumab in Patients With Hepatocellular Carcinoma (HCC) Undergoing Transarterial Chemoembolization (TACE)

Hepatocellular Carcinoma

United States
University of Michigan Rogel Cancer Center

Completed

A Pilot Trial to Determine the Extent of Inter- and Intra-Treatment Organ Motion Using Active Breathing Control Device (ABC) in Patients With Pancreatic Cancer

Pancreatic Cancer

United States
University of Michigan Rogel Cancer Center

Completed

Phase II Trial Evaluating Axitinib In Patients With Unresectable, Recurrent Or Metastatic Head And Neck Cancer

Head and Neck Squamous Cell Carcinoma

United States
University of Michigan Rogel Cancer Center

Completed

Chemoradiation and Tetrathiomolybdate (TM) in Patients With Esophageal Carcinoma

Esophageal Carcinoma

United States
University of Michigan Rogel Cancer Center

Completed

Blood Stem Cell Transplantation for the Treatment of Older Patients With Acute Myelogenous Leukemia

Acute Myelogenous Leukemia

United States
University of Michigan Rogel Cancer Center

Completed

Imaging Biomarker for Early Detection of Treatment Efficacy During Breast Cancer Neoadjuvant Chemotherapy

Breast Cancer

United States
University of Michigan Rogel Cancer Center

Terminated

Palonosetron for the Treatment of Nausea and Vomiting in Terminally Ill Patients (HUM21469)

Nausea | Vomiting | Terminally Ill

United States
University of Michigan Rogel Cancer Center

Terminated

A Study of Mitomycin C, Irinotecan, and Cetuximab

Colorectal Cancer

United States
University of Michigan Rogel Cancer Center

Terminated

Cetuximab and Radiation Therapy in Laryngeal Cancer Patients Who Have Responded to One Cycle of Chemotherapy (SPORE)

Cancer of Larynx

United States
University of Michigan Rogel Cancer Center

Terminated

Clinical Trial Of Neoadjuvant Chemotherapy (NAC)In Upper Tract Urothelial Carcinoma (UTUC)

Bladder Cancer | Urothelial Cancer

United States
University of Michigan Rogel Cancer Center

Completed

Benefits of Exercise Training in Head and Neck Cancer Patients Undergoing Organ-Preserving Definitive Therapy

Head and Neck Squamous Cell Carcinoma

United States

3

Subscribe